Payment overview · 2025
General Payments
$734.69
52 reported records · 14 companies
Healthcare provider profile · identity verified
Richard Michael Clark, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · EVANSVILLE, IN · NPI 1437387040
Verified facts
What the public records show
CMS Open Payments records show Richard Michael Clark, D.O. received $734.69 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $215.44 | 29.3% | 20 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $112.87 | 15.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.23 | 13.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.59 | 11.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.12 | 8.7% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $32.93 | 4.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.81 | 2.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.54 | 2.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.18 | 2.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.18 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.10 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.89 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.94 | 1.8% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $12.87 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $689.69 | 51 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $162.82 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $159.47 | 15 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $112.87 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.12 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $62.94 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.57 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.59 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.59 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.04 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.94 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $12.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 81 |
| Omeprazole | Omeprazole | 291 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 62 |
| Losartan Potassium | Losartan Potassium | 215 | 49 |
| Lisinopril | Lisinopril | 196 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 44 |
| Gabapentin | Gabapentin | 181 | 34 |
| Furosemide | Furosemide | 169 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 39 |
| Meloxicam | Meloxicam | 160 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 37 |
| Lorazepam | Lorazepam | 150 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 37 |
| Ozempic | Semaglutide | 138 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 25 |
| Azithromycin | Azithromycin | 126 | 90 |
| Tramadol Hcl | Tramadol Hcl | 122 | 23 |
| Metformin Hcl Er | Metformin Hcl | 119 | 33 |
| Alprazolam | Alprazolam | 118 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 26 |
| Sertraline Hcl | Sertraline Hcl | 112 | 20 |
| Metformin Hcl | Metformin Hcl | 109 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 39 |
| Potassium Chloride | Potassium Chloride | 98 | 22 |
| Montelukast Sodium | Montelukast Sodium | 93 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 20 |
| Prednisone | Prednisone | 91 | 53 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 89 | 23 |
| Atenolol | Atenolol | 87 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 24 |
| Trazodone Hcl | Trazodone Hcl | 78 | 20 |
| Simvastatin | Simvastatin | 77 | 21 |
| Methylprednisolone | Methylprednisolone | 75 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 20 |
| Clonazepam | Clonazepam | 69 | 14 |
| Allopurinol | Allopurinol | 67 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 25 |
| Famotidine | Famotidine | 64 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 28 |
| Buspirone Hcl | Buspirone Hcl | 59 | suppressed |
| Ezetimibe | Ezetimibe | 59 | 14 |
| Bupropion Xl | Bupropion Hcl | 56 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 11 |
| Glipizide | Glipizide | 54 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 11 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 13 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Spironolactone | Spironolactone | 41 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 14 |
| Cephalexin | Cephalexin | 35 | 24 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 19 |
| Baclofen | Baclofen | 33 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 17 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 13 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Armodafinil | Armodafinil | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Mysoline | Primidone | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $734.69 · 52 records | ABBVIE INC. | AIRSUPRA, Auvelity, Azstarys, BREZTRI, FANAPT, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SX-ONE MICROKNIFE, UBRELVY, VOQUEZNA, VRAYLAR, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error